Continuous Glucose Monitoring Parameter and Oral Glucose Tolerance Testing (OGTT) Parameters in Children and Young Adults With Cystic Fibrosis (CF)
NCT07930884, Not applicable, Recruiting, Northwell Health
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Continuous Glucose Monitoring Parameter and Oral Glucose Tolerance Testing (OGTT) Parameters in Children and Young Adults With Cystic Fibrosis (CF) | ClinicalTrials.gov |
| NCT number | NCT07930884 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 30 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Northwell Health | ClinicalTrials.gov |
| Conditions | Cystic Fibrosis Related Diabetes, CGM | ClinicalTrials.gov |
| Interventions | Continuous Glucose Monitor | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Average Blood Glucose Level from Continuous Glucose Monitoring | Up to 10 days of CGM wear (within 3 months of the Oral Glucose Tolerance Test). | Mean glucose level recorded over the continuous glucose monitoring (CGM) wear period (mg/dL) | ClinicalTrials.gov |
| Secondary | Percentage of Time Glucose Exceeds 150 mg/dL from Continuous Glucose Monitoring | Up to 10 days of CGM wear (within 3 months of the Oral Glucose Tolerance Test). | The proportion of time during the CGM wear period that glucose levels were above 150 mg/dL (%) | ClinicalTrials.gov |
| Secondary | Percentage of Time Glucose Exceeds 180 mg/dL from Continuous Glucose Monitoring | Up to 10 days of CGM wear (within 3 months of the Oral Glucose Tolerance Test). | The proportion of time during the CGM wear period that glucose levels were above 180 mg/dL (%) | ClinicalTrials.gov |
| Secondary | Fasting Plasma Glucose Level from Oral Glucose Tolerance Test | Single measurement at the start of the OGTT (within 3 months of CGM wear). | Plasma glucose level measured after an overnight fast, as part of the Oral Glucose Tolerance Test (OGTT) (mg/dL) | ClinicalTrials.gov |
| Secondary | 1 hour Plasma Glucose Level from Oral Glucose Tolerance Test | Single measurement 1 hour after glucose load (within 3 months of CGM wear). | Plasma glucose level measured 1 hour after glucose administration as part of the Oral Glucose Tolerance Test (OGTT) (mg/dL) | ClinicalTrials.gov |
| Secondary | 2-Hour Plasma Glucose Level from Oral Glucose Tolerance Test | Single measurement 2 hours after glucose load (within 3 months of CGM wear). | Plasma glucose level measured 2 hours after glucose load administration during the OGTT (mg/dL) | ClinicalTrials.gov |
| Secondary | Forced Expiratory Volume in 1 Second (FEV1) as a Percentage of Predicted | Within 3 months of CGM placement (standard of care assessment). | Lung function parameter reflecting the volume of air exhaled in the first second during a forced breath, expressed as a percentage of the predicted value. (%) | ClinicalTrials.gov |
| Secondary | Forced Vital Capacity (FVC) as a Percentage of Predicted | Within 3 months of CGM placement (standard of care assessment). | Lung function parameter reflecting the total volume of air exhaled during a forced breath, expressed as a percentage of the predicted value (%) | ClinicalTrials.gov |
| Secondary | Hemoglobin A1c (HbA1c) Level | At the time of OGTT (within 3 months of CGM wear). | A measure of average blood glucose level (%) | ClinicalTrials.gov |
| Secondary | Body Mass Index (BMI) Z-Score | Within 3 months of CGM placement (standard of care assessment). | Age- and sex-adjusted Body Mass Index standardized score, reflecting nutritional status (z-score) | ClinicalTrials.gov |
| Secondary | Response to Survey Question on CFRD Screening Preferences | After 10 days of CGM wear | Participant's (and/or parent/guardian's) response to the Likert scale questions regarding preferences for Cystic Fibrosis Related Diabetes | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 6
The papers the trial lists on ClinicalTrials.gov.
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.